This trial and its updated analysis showed that the addition of capivasertib to fulvestrant resulted in a significant improvement of progression-free survival, objective response rate (ORR) [102] and overall survival [103] in participants with aromatase inhibitor-resistant ER-positive, HER2−negative advanced breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.